YY1 promotes HDAC1 expression and decreases sensitivity of hepatocellular carcinoma cells to HDAC inhibitor
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1713 views | HTML 1911 views | ?
Sheng Dong1, Xiang Ma1, Zusen Wang1, Bing Han1, Hao Zou1, Zehua Wu1, Yunjin Zang2 and Likun Zhuang2
1Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China
2Institute of Transplantation Science, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China
Likun Zhuang, email: [email protected]
Yunjin Zang, email: [email protected]
Keywords: YY1, HDAC1, HDAC inhibitor, HCC, drug sensitivity
Received: February 20, 2017 Accepted: April 05, 2017 Published: April 18, 2017
YY1 is a DNA-binding transcription factor and reported to be involved in cancer progression. Histone deacetylase inhibitor (HDACi) could inhibit proliferation and promote apoptosis of Hepatocellular carcinoma (HCC) cells. However, it is unclear about the roles of YY1 in the sensitivity of HCC cells to HDACi. In this study, firstly, we identified two drug-response profiles to HDACi in HCC cell lines, while our results showed that HDAC1 expression was positively correlated with YY1 in HCC cell lines and primary tumor tissues. Secondly, YY1 decreased the sensitivity of HCC cells to HDACi in vitro and in vivo. Furthermore, we found that YY1 promoted HDAC1 expression by binding to its promoter, while HDAC1 in turn up-regulated the expression of YY1. In conclusion, our results showed that YY1 could reduce the sensitivity of HCC cells to HDACi and might be a potential therapeutic target in HCC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.